RNS

ROCKVILLE, Maryland - 1 December 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, since 31 October 2023 it has issued 133,442 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

ROCKVILLE, MD, November 30, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 27 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 5,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.

ROCKVILLE, MD, November 17, 2023: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 14 November 2023, as per a filing lodged with the U.S. Securities and Exchange Commission, John Johnston, a Non-Executive Director of the Company, exercised options over 10,000 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate.